Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
VistaGen Therapeutics announces data highlighting MOA of PH94B nasal spray » 08:42
03/22/21
03/22
08:42
03/22/21
08:42
VTGN

VistaGen Therapeutics

$2.34 /

+0.175 (+8.10%)

VistaGen Therapeutics…

VistaGen Therapeutics announced that data highlighting the proposed mechanism of action of its Phase 3 investigational drug candidate, PH94B nasal spray, were recently presented in a poster session at the Anxiety and Depression Association of America's 2021 Virtual Annual Conference. PH94B is designed with potential to provide rapid-onset acute treatment of anxiety for millions of individuals suffering from social anxiety disorder without directly activating gamma-amino butyric acid receptors. PH94B's MOA is, therefore, fundamentally differentiated from the MOA of benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators. Among VistaGen's core goals is for PH94B to displace these and other widely-used but highly-addictive benzodiazepines in the acute treatment paradigm for SAD and other anxiety disorders and phobias. PH94B is an investigational odorless pherine nasal spray entering Phase 3 clinical development in the U.S. for the acute treatment of anxiety in adults with SAD, the third most common mental health disorder among Americans, affecting approximately 20 million individuals. PH94B also has therapeutic potential in a wide range of additional anxiety disorders and phobias. Self-administered in microgram-level doses, in Phase 2 clinical studies, PH94B produced rapid-onset anti-anxiety effects within approximately 15 minutes, without the troubling side effects associated with benzodiazepines. To help differentiate PH94B's mechanism of action from that of benzodiazepines, VistaGen studied whether PH94B had positive modulatory effects on GABA receptors. Key results in the recent ADAA poster presentation include the following: PH94B had no significant effect on GABA potentiation at doses up to 10 micromolar, compared to the 300 percent potentiation induced by diazepam, a commonly-prescribed benzodiazepine. The concentration of PH94B that gives the half-maximal response could not be calculated for PH94B, whereas diazepam's half-maximal response was 72 nanomolar. PH94B had no agonist or antagonist effects on GABA receptors compared to the effect of GABA and bicuculline, respectively.

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$2.34 /

+0.175 (+8.10%)

VTGN VistaGen Therapeutics
$2.34 /

+0.175 (+8.10%)

02/18/21 Jefferies
Jefferies starts VistaGen at Buy, sees 'big upside' potential for anxiety drug
02/18/21 Jefferies
VistaGen Therapeutics initiated with a Buy at Jefferies
01/04/21 William Blair
VistaGen upgraded on 'clearly skewed' risk/reward at William Blair
01/04/21 William Blair
VistaGen Therapeutics upgraded to Outperform from Market Perform at William Blair
VTGN VistaGen Therapeutics
$2.34 /

+0.175 (+8.10%)

  • 18
    Dec
Over a month ago
Syndicate
VistaGen Therapeutics files $250M mixed securities shelf  17:04
03/15/21
03/15
17:04
03/15/21
17:04
VTGN

VistaGen Therapeutics

$2.28 /

-0.055 (-2.36%)

 
ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$2.28 /

-0.055 (-2.36%)

VTGN VistaGen Therapeutics
$2.28 /

-0.055 (-2.36%)

02/18/21 Jefferies
Jefferies starts VistaGen at Buy, sees 'big upside' potential for anxiety drug
02/18/21 Jefferies
VistaGen Therapeutics initiated with a Buy at Jefferies
01/04/21 William Blair
VistaGen upgraded on 'clearly skewed' risk/reward at William Blair
01/04/21 William Blair
VistaGen Therapeutics upgraded to Outperform from Market Perform at William Blair
VTGN VistaGen Therapeutics
$2.28 /

-0.055 (-2.36%)

  • 18
    Dec
Hot Stocks
VistaGen Therapeutics announces preclinical data on PH10 nasal spray » 08:45
03/11/21
03/11
08:45
03/11/21
08:45
VTGN

VistaGen Therapeutics

$2.16 /

-0.08 (-3.58%)

VistaGen Therapeutics…

VistaGen Therapeutics announced preclinical data demonstrating that the potential mechanism of action of PH10, its Phase 2 investigational pherine nasal spray with potential as a rapid-onset, stand-alone treatment for major depressive disorder, does not involve direct activation of GABA-A receptors, in distinct contrast to the mechanism of action of benzodiazepines, which act as direct positive modulators of GABA-A receptors. Instead, PH10 is designed to engage receptors in nasal chemosensory neurons which in turn regulate neurons in the limbic amygdala that release excitatory neurotransmitters producing rapid-onset antidepressant effects. In September 2020, the U.S. Food and Drug Administration released a Drug Safety Communication detailing the risks associated with use of benzodiazepines. According to the FDA's communication, 92 million benzodiazepine prescriptions were filled in 2019. The DSC detailed safety concerns regarding the serious risks of abuse, addiction, physical dependence, and withdrawal reactions linked to long-term use of benzodiazepines, and the FDA announced that it is requiring an updated Boxed Warning, the FDA's most prominent type of safety warning, for all benzodiazepine medications. Recent studies have shown that there has been an exacerbation of existing depression symptoms, with U.S. adults showing three times as many symptoms of depression during the COVID-19 pandemic, creating a critical need for new and differentiated alternatives for treatment of MDD. PH10 may have the potential to displace existing SSRIs and SNRIs as a stand-alone alternative in the drug treatment paradigm for depression disorders. PH10 is a new generation antidepressant with a mechanism of action that is designed to be fundamentally different from all current FDA-approved antidepressants. After intranasal administration, a non-systemic microgram-level dose of PH10 binds to nasal chemosensory receptors that, in turn, activate key neural circuits in the brain that can lead to rapid-onset antidepressant effects, but without the psychological side effects or safety concerns that may be caused by rapid-onset ketamine-based therapy, including both intravenous ketamine and esketamine nasal spray, or the side effects and safety concerns of current oral antidepressants that may take many weeks to become effective.

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$2.16 /

-0.08 (-3.58%)

VTGN VistaGen Therapeutics
$2.16 /

-0.08 (-3.58%)

02/18/21 Jefferies
Jefferies starts VistaGen at Buy, sees 'big upside' potential for anxiety drug
02/18/21 Jefferies
VistaGen Therapeutics initiated with a Buy at Jefferies
01/04/21 William Blair
VistaGen upgraded on 'clearly skewed' risk/reward at William Blair
01/04/21 William Blair
VistaGen Therapeutics upgraded to Outperform from Market Perform at William Blair
VTGN VistaGen Therapeutics
$2.16 /

-0.08 (-3.58%)

  • 18
    Dec
Initiation
Jefferies starts VistaGen at Buy, sees 'big upside' potential for anxiety drug » 06:37
02/18/21
02/18
06:37
02/18/21
06:37
VTGN

VistaGen Therapeutics

$2.06 /

+0.07 (+3.53%)

As previously reported,…

As previously reported, Jefferies analyst Andrew Tsai initiated coverage of VistaGen Therapeutics with a Buy rating and $6 price target. The company's lead asset, PH94B, is a fast-acting nasal spray whose "compelling" Phase 2 data for social anxiety spurred an FDA "buy-in" on a "fairly de-risked" Phase 3 program, Tsai tells investors. Based on his work and checks with doctors, he thinks PH94B could become the first FDA-approved therapy for acute social anxiety disorder, or SAD, said Tsai, who thinks the Street is overlooking PH94B's "upside potential."

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$2.06 /

+0.07 (+3.53%)

VTGN VistaGen Therapeutics
$2.06 /

+0.07 (+3.53%)

02/18/21 Jefferies
VistaGen Therapeutics initiated with a Buy at Jefferies
01/04/21 William Blair
VistaGen upgraded on 'clearly skewed' risk/reward at William Blair
01/04/21 William Blair
VistaGen Therapeutics upgraded to Outperform from Market Perform at William Blair
12/22/20 Maxim
VistaGen Therapeutics price target raised to $5 from $3 at Maxim
VTGN VistaGen Therapeutics
$2.06 /

+0.07 (+3.53%)

  • 18
    Dec
Initiation
VistaGen Therapeutics initiated with a Buy at Jefferies » 05:36
02/18/21
02/18
05:36
02/18/21
05:36
VTGN

VistaGen Therapeutics

$2.06 /

+0.07 (+3.53%)

Jefferies analyst Andrew…

Jefferies analyst Andrew Tsai initiated coverage of VistaGen Therapeutics with a Buy rating and $6 price target.

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$2.06 /

+0.07 (+3.53%)

VTGN VistaGen Therapeutics
$2.06 /

+0.07 (+3.53%)

01/04/21 William Blair
VistaGen upgraded on 'clearly skewed' risk/reward at William Blair
01/04/21 William Blair
VistaGen Therapeutics upgraded to Outperform from Market Perform at William Blair
12/22/20 Maxim
VistaGen Therapeutics price target raised to $5 from $3 at Maxim
12/17/20
VistaGen Therapeutics announces public offering
VTGN VistaGen Therapeutics
$2.06 /

+0.07 (+3.53%)

  • 18
    Dec
Earnings
VistaGen reports Q3 EPS (7c), consensus (5c) » 16:33
02/11/21
02/11
16:33
02/11/21
16:33
VTGN

VistaGen Therapeutics

$1.99 /

-0.03 (-1.49%)

Reports Q3 revenue…

Reports Q3 revenue $313,600, consensus $210,000. "Calendar 2020 was transformative, highlighted by closing a PH94B partnership, a positive meeting with the FDA regarding the key aspects of the study design for our upcoming pivotal Phase 3 studies of our PH94B nasal spray in social anxiety disorder and, during the most recent quarter, closing a $100 million financing which involved significant participation from leading healthcare institutional investors such as Acuta Capital, New Enterprise Associates, OrbiMed and Venrock Healthcare Capital Partners, among others. We are encouraged by these transformative milestones. Together, they have further advanced our tenacious pursuit to bring life-changing medications to the millions affected by anxiety, depression and other mental health challenges worldwide," said Shawn Singh, Chief Executive Officer of VistaGen.

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$1.99 /

-0.03 (-1.49%)

VTGN VistaGen Therapeutics
$1.99 /

-0.03 (-1.49%)

01/04/21 William Blair
VistaGen upgraded on 'clearly skewed' risk/reward at William Blair
01/04/21 William Blair
VistaGen Therapeutics upgraded to Outperform from Market Perform at William Blair
12/22/20 Maxim
VistaGen Therapeutics price target raised to $5 from $3 at Maxim
12/17/20
VistaGen Therapeutics announces public offering
VTGN VistaGen Therapeutics
$1.99 /

-0.03 (-1.49%)

  • 18
    Dec
Over a quarter ago
Hot Stocks
VistaGen Therapeutics regains full compliance with Nasdaq listing requirements » 08:19
01/06/21
01/06
08:19
01/06/21
08:19
VTGN

VistaGen Therapeutics

$2.03 /

-0.245 (-10.77%)

VistaGen Therapeutics…

VistaGen Therapeutics announced that it received notice from The Nasdaq Stock Market on January 5, 2021 that VistaGen has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. VistaGen is now in full compliance with all applicable listing standards, and Nasdaq considers the matter closed.

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$2.03 /

-0.245 (-10.77%)

VTGN VistaGen Therapeutics
$2.03 /

-0.245 (-10.77%)

01/04/21 William Blair
VistaGen upgraded on 'clearly skewed' risk/reward at William Blair
01/04/21 William Blair
VistaGen Therapeutics upgraded to Outperform from Market Perform at William Blair
12/22/20 Maxim
VistaGen Therapeutics price target raised to $5 from $3 at Maxim
12/17/20
VistaGen Therapeutics announces public offering
VTGN VistaGen Therapeutics
$2.03 /

-0.245 (-10.77%)

  • 18
    Dec
Upgrade
VistaGen upgraded on 'clearly skewed' risk/reward at William Blair » 09:00
01/04/21
01/04
09:00
01/04/21
09:00
VTGN

VistaGen Therapeutics

$1.95 /

+0.18 (+10.20%)

William Blair analyst Tim…

William Blair analyst Tim Lugo upgraded VistaGen Therapeutics to Outperform from Market Perform. The stock's risk/reward is "clearly skewed" to the upside as the company advances lead asset PH94B into a pivotal Phase III U.S. study in social anxiety disorder during second quarter of 2021 and a global Phase III study by year-end 2021, Lugo tells investors in a research note. PH94B offers a new nonsystemic mechanism of action in this large indication, which affects over 17M in the United States alone, the analyst points out. He sees the company's enterprise value of around $130M as attractive and notes that his net present derived fair value for $9 per share assumes a low-single-digit penetration rate in second-line and mid-single-digit penetration in third-line therapy into the "large" social anxiety market.

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$1.95 /

+0.18 (+10.20%)

VTGN VistaGen Therapeutics
$1.95 /

+0.18 (+10.20%)

01/04/21 William Blair
VistaGen Therapeutics upgraded to Outperform from Market Perform at William Blair
12/22/20 Maxim
VistaGen Therapeutics price target raised to $5 from $3 at Maxim
12/17/20
VistaGen Therapeutics announces public offering
VTGN VistaGen Therapeutics
$1.95 /

+0.18 (+10.20%)

  • 18
    Dec
Upgrade
VistaGen Therapeutics upgraded to Outperform from Market Perform at William Blair » 06:30
01/04/21
01/04
06:30
01/04/21
06:30
VTGN

VistaGen Therapeutics

$1.95 /

+0.18 (+10.20%)

William Blair analyst Tim…

William Blair analyst Tim Lugo upgraded VistaGen Therapeutics to Outperform from Market Perform.

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$1.95 /

+0.18 (+10.20%)

VTGN VistaGen Therapeutics
$1.95 /

+0.18 (+10.20%)

12/22/20 Maxim
VistaGen Therapeutics price target raised to $5 from $3 at Maxim
12/17/20
VistaGen Therapeutics announces public offering
VTGN VistaGen Therapeutics
$1.95 /

+0.18 (+10.20%)

  • 18
    Dec
Hot Stocks
VistaGen Therapeutics announces publication on neuroactive nasal sprays » 09:10
12/30/20
12/30
09:10
12/30/20
09:10
VTGN

VistaGen Therapeutics

$1.50 /

+0.19 (+14.50%)

VistaGen Therapeutics…

VistaGen Therapeutics announced that Dr. Louis Monti, VistaGen Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, authored an article published in CNS Spectrums, a Cambridge University Press journal, on the proposed mechanism of action of the Company's investigational neuroactive nasal sprays, PH94B and PH10, currently in development as potential rapid-onset treatments for anxiety and depression disorders, respectively.1 The publication details the proposed neural circuits mediating the mechanism of action of pherines, including PH94B and PH10, which are synthetic neuroactive steroids designed to engage nasal chemosensory receptors and produce rapid-onset anxiolytic and antidepressant effects, respectively. PH94B and PH10, which are administered in microgram-level doses, are designed to achieve therapeutic benefits without requiring systemic uptake, potentially avoiding the side effects and safety concerns often associated with current antidepressants and anxiolytics, including benzodiazepines.

ShowHide Related Items >><<
VTGN VistaGen Therapeutics
$1.50 /

+0.19 (+14.50%)

VTGN VistaGen Therapeutics
$1.50 /

+0.19 (+14.50%)

12/22/20 Maxim
VistaGen Therapeutics price target raised to $5 from $3 at Maxim
12/17/20
VistaGen Therapeutics announces public offering
VTGN VistaGen Therapeutics
$1.50 /

+0.19 (+14.50%)

  • 18
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.